This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
This article is part of WikiProject AIDS, an attempt to build a comprehensive, detailed, and accessible guide to AIDS, HIV, and related topics on Wikipedia. If you would like to participate in the project, you can choose to edit this article, or visit the project page for more information.AIDSWikipedia:WikiProject AIDSTemplate:WikiProject AIDSAIDS articles
Latest comment: 18 years ago1 comment1 person in discussion
I've overhauled this page. Some points which aren't immediately obvious:
The statement on potency compared with other antiretrovirals isn't supported by the major clinical trials of ddC, where there's no statistically significant difference between the ddC arms and the other nRTI arms. See eg Moyle 1998 for a review. The major reasons why ddC isn't used are the high frequency of peripheral neuropathy and the tid frequency.
I'm not sure where the "only use with ZDV" statement originated; I can find no evidence for this. I've recast this to say "don't use with ZDV, ddI, d4T", as it states in the latest tx guidelines.
